• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NHLBI funds second phase of COPDGene project

NHLBI funds second phase of COPDGene project

August 9, 2012
CenterWatch Staff

The National Heart, Lung, and Blood Institute (NHLBI)has decided to fund the second phase (2012-2017) of the COPDGene project through R01 grants to National Jewish Health and the Brigham and Women’s Hospital.

The grant enables scientists to build on the first phase of the COPDGene study, lead by theCOPD Foundation (COPDF), in analyzing the human genome comprehensively to find additional genetic predispositions to developing COPD (chronic obstructive pulmonary disease). By understanding the biological mechanisms causing COPD, the study could lead to specific treatments that would prevent further progression of the disease.

“The importance of this study, and NHLBI’s continued funding, is paramount,” said John W. Walsh, president and co-founder of the COPDF. “This research has the potential to identify the set of genes that controls susceptibility to COPD. Such information would aid the development of new therapies that could improve the quality of life for individuals with COPD—and potentially save lives.”

The COPDGene cohort of 10,171 subjects was created by medical centers across the U.S. and is composed of subjects with a background of heavy smoking and who either have COPD or are at risk for developing this disease. In the second phase of this project, follow-up visits at a five-year interval from the initial visit, will be done on all available COPDGene subjects in order to determine longitudinal changes in disease development and progression.

Walsh added, “Ultimately, by providing a greater understanding of COPD, the COPDGene Study lays a solid foundation for the development of personalized therapy.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing